About Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CYTX
CUSIP23283K10
Phone858-458-0900
Debt
Debt-to-Equity RatioN/A
Current Ratio0.81%
Quick Ratio0.63%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.69 million
Price / Sales6.41
Cash FlowN/A
Price / CashN/A
Book Value$0.22 per share
Price / Book1.27
Profitability
EPS (Most Recent Fiscal Year)($0.65)
Net Income$-22,680,000.00
Net Margins-418.36%
Return on Equity-210.47%
Return on Assets-68.94%
Miscellaneous
Employees37
Outstanding Shares61,610,000
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics shares reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company earned $1.50 million during the quarter, compared to the consensus estimate of $2 million. Cytori Therapeutics had a negative net margin of 418.36% and a negative return on equity of 210.47%. View Cytori Therapeutics' Earnings History.
When is Cytori Therapeutics' next earnings date?
What price target have analysts set for CYTX?
3 brokers have issued twelve-month price objectives for Cytori Therapeutics' stock. Their predictions range from $1.65 to $2.30. On average, they anticipate Cytori Therapeutics' share price to reach $1.9833 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (3/8/2018)
- 2. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)
Who are some of Cytori Therapeutics' key competitors?
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Richard James Hawkins, Chairman of the Board (Age 68)
- Marc H. Hedrick M.D., President, Chief Executive Officer, Director (Age 52)
- Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance (Age 35)
- Seijiro N. Shirahama, President , Asia Pacific (Age 60)
- John David Harris, Vice President, General Manager - Cell Therapy
- Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
- Mark Marino M.D., Chief Medical Officer
- Gregg A. Lapointe, Director
- Gary A. Lyons, Independent Director (Age 66)
- Ronald A. Martell, Independent Director (Age 54)
Has Cytori Therapeutics been receiving favorable news coverage?
Media coverage about CYTX stock has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a daily sentiment score of 0.20 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.28.
How big of a company is Cytori Therapeutics?
Cytori Therapeutics has a market capitalization of $17.38 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (CYTX)
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytori Therapeutics (NASDAQ:CYTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Cytori Therapeutics in the last 12 months. Their average twelve-month price target is $1.9833, suggesting that the stock has a possible upside of 608.33%. The high price target for CYTX is $2.30 and the low price target for CYTX is $1.65. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.9833 | $1.9833 | $3.65 | $3.65 |
| Price Target Upside: | 608.33% upside | 539.78% upside | 1,251.85% upside | 651.03% upside |
Cytori Therapeutics (NASDAQ:CYTX) Consensus Price Target History
Cytori Therapeutics (NASDAQ:CYTX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/28/2018 | Maxim Group | Set Price Target | Buy | $2.00 | High |  |
| 3/9/2018 | B. Riley | Upgrade | Neutral -> Buy | | Low | |
| 2/22/2018 | Laidlaw | Reiterated Rating | Buy -> Buy | $1.65 | Medium | |
| 6/28/2016 | Roth Capital | Reiterated Rating | Buy | $11.00 | N/A | |
(Data available from 4/20/2016 forward)
Cytori Therapeutics (NASDAQ:CYTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cytori Therapeutics (NASDAQ CYTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 6.03%
Cytori Therapeutics (NASDAQ CYTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/13/2018 | Ag Postfinance | Major Shareholder | Sell | 286,982 | $0.31 | $88,964.42 | 5,118,627 | |
| 2/9/2018 | Ag Postfinance | Major Shareholder | Sell | 236,155 | $0.34 | $80,292.70 | 5,311,451 | |
| 1/11/2018 | Bank Sa Swissquote | Major Shareholder | Sell | 72,630 | $0.34 | $24,694.20 | 5,496,655 | |
| 1/9/2018 | Bank Sa Swissquote | Major Shareholder | Sell | 100,000 | $0.38 | $38,000.00 | 5,496,655 | |
| 8/10/2016 | John David Harris | VP | Buy | 2,500 | $2.03 | $5,075.00 | 7,000 | |
| 6/14/2016 | Gail K Naughton | Director | Buy | 1,000 | $2.10 | $2,100.00 | 2,400 | |
| 5/13/2016 | John David Harris | VP | Buy | 2,000 | $2.71 | $5,420.00 | 2,000 | |
| 3/9/2016 | David Rickey | Director | Buy | 150,000 | $0.19 | $28,500.00 | | |
| 9/3/2015 | Tommy G Thompson | Director | Buy | 25,449 | $0.37 | $9,416.13 | | |
| 9/2/2015 | Jeremy B Hayden | VP | Buy | 8,200 | $0.36 | $2,952.00 | 26,200 | |
| 8/28/2015 | David Rickey | Director | Buy | 56,000 | $0.31 | $17,360.00 | | |
| 8/28/2015 | Marc H Hedrick | CEO | Buy | 11,200 | $0.31 | $3,472.00 | 504,611 | |
| 8/27/2015 | David Rickey | Director | Buy | 75,000 | $0.31 | $23,250.00 | | |
| 8/21/2015 | David Rickey | Director | Buy | 50,000 | $0.38 | $19,000.00 | | |
| 8/21/2015 | Marc H Hedrick | CEO | Buy | 5,000 | $0.38 | $1,900.00 | 504,611 | |
| 8/20/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.40 | $4,000.00 | 504,611 | |
| 8/19/2015 | David Rickey | Director | Buy | 48,600 | $0.39 | $18,954.00 | | |
| 8/19/2015 | Steven Kesten | VP | Buy | 6,000 | $0.39 | $2,340.00 | 2,201 | |
| 8/18/2015 | David Rickey | Director | Buy | 51,400 | $0.39 | $20,046.00 | | |
| 8/18/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.39 | $3,900.00 | 504,611 | |
| 8/18/2015 | Tiago Girao | CFO | Buy | 25,000 | $0.39 | $9,750.00 | 88,000 | |
| 11/13/2014 | David Rickey | Director | Buy | 20,000 | $0.47 | $9,400.00 | | |
| 11/12/2014 | David Rickey | Director | Buy | 200,000 | $0.39 | $78,000.00 | | |
| 11/12/2014 | Tiago Girao | CFO | Buy | 60,000 | $0.39 | $23,400.00 | | |
| 11/11/2014 | Tiago Girao | CFO | Buy | 15,889 | $0.39 | $6,196.71 | | |
| 6/5/2014 | David Rickey | Director | Buy | 30,000 | $2.34 | $70,200.00 | | |
| 9/12/2013 | David Rickey | Director | Buy | 7,100 | $2.55 | $18,105.00 | | |
| 9/11/2013 | David Rickey | Director | Buy | 2,000 | $2.58 | $5,160.00 | | |
| 9/9/2013 | David Rickey | Director | Buy | 5,000 | $2.31 | $11,550.00 | | |
| 9/5/2013 | David Rickey | Director | Buy | 2,000 | $2.24 | $4,480.00 | | |
| 9/3/2013 | David Rickey | Director | Buy | 7,000 | $2.14 | $14,980.00 | | |
| 8/30/2013 | Tommy G Thompson | Director | Buy | 5,000 | $2.14 | $10,700.00 | | |
| 12/19/2012 | Lloyd H Dean | Director | Buy | 25,000 | $2.85 | $71,250.00 | | |
| 12/19/2012 | Marc H Hedrick | President | Buy | 10,000 | $2.85 | $28,500.00 | | |
(Data available from 1/1/2013 forward)
Cytori Therapeutics (NASDAQ CYTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cytori Therapeutics (CYTX) Given a $10.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 19 at 12:16 PM |
| Cytori Therapeutics (CYTX) Upgraded at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM |
| B. Riley Lowers Cytori Therapeutics (CYTX) to Neutral
www.americanbankingnews.com - April 16 at 2:58 PM |
| Cytori Therapeutics (CYTX) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 2:31 PM |
| ValuEngine Downgrades Cytori Therapeutics (CYTX) to Strong Sell
www.americanbankingnews.com - April 3 at 5:16 PM |
| B. Riley Reaffirms Hold Rating for Cytori Therapeutics (CYTX)
www.americanbankingnews.com - April 1 at 3:10 PM |
| Comparing Cytori Therapeutics (CYTX) & Restoration Robotics (HAIR)
www.americanbankingnews.com - April 1 at 11:08 AM |
| Cytori Therapeutics Inc (CYTX) Given $1.45 Average Price Target by Analysts
www.americanbankingnews.com - March 31 at 3:18 PM |
| Cytori Therapeutics (CYTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 1:07 PM |
| Maxim Group Analysts Give Cytori Therapeutics (CYTX) a $2.00 Price Target
www.americanbankingnews.com - March 28 at 7:04 PM |
 | Cytori Therapeutics (CYTX) Reports Full Enrollment in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary Incontinence
www.streetinsider.com - March 28 at 5:18 PM |
 | Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
finance.yahoo.com - March 28 at 5:18 PM |
| Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant
finance.yahoo.com - March 28 at 8:27 AM |
| Cytori Therapeutics (CYTX) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM |
| Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT
finance.yahoo.com - March 18 at 6:23 PM |
| Cytori Therapeutics (CYTX) PT Set at $2.00 by Maxim Group
www.americanbankingnews.com - March 10 at 5:10 PM |
| Cytori Therapeutics (CYTX) Issues Earnings Results
www.americanbankingnews.com - March 10 at 9:56 AM |
| Cytori Therapeutics (CYTX) Stock Rating Upgraded by B. Riley
www.americanbankingnews.com - March 9 at 8:33 PM |
 | Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:20 AM |
 | Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:20 AM |
| Cytori reports 4Q loss
finance.yahoo.com - March 9 at 8:20 AM |
| Cytori Therapeutics (CYTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 8 at 8:48 PM |
| Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed Lately
finance.yahoo.com - March 8 at 6:44 PM |
| Cytori Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 8 at 6:44 PM |
| Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
finance.yahoo.com - March 8 at 6:44 PM |
| FY2017 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)
www.americanbankingnews.com - March 8 at 7:54 AM |
| Laidlaw Resumes Cytori Therapeutics, Inc. (CYTX) at Buy - StreetInsider.com
www.streetinsider.com - February 24 at 8:15 AM |
| Cytori Therapeutics' (CYTX) "Buy" Rating Reiterated at Laidlaw
www.americanbankingnews.com - February 22 at 9:42 PM |
| Cytori to Webcast Fourth Quarter Financial Results on March 8th
finance.yahoo.com - February 22 at 5:37 PM |
| Financial Comparison: Align Technology (ALGN) & Cytori Therapeutics (CYTX)
www.americanbankingnews.com - February 22 at 11:50 AM |
| Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress
finance.yahoo.com - February 15 at 9:29 AM |
| Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $88,964.42 in Stock
www.americanbankingnews.com - February 14 at 6:32 PM |
| Cytori Therapeutics (CYTX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 13 at 9:44 PM |
| Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - February 13 at 1:28 PM |
| Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock
www.americanbankingnews.com - February 12 at 6:46 PM |
| Cytori Therapeutics Announces Inducement Grants for New Employees
finance.yahoo.com - February 10 at 9:43 AM |
| Comparing Antares Pharma (ATRS) and Cytori Therapeutics (CYTX)
www.americanbankingnews.com - February 9 at 3:04 PM |
| Cytori Therapeutics (CYTX) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - January 22 at 6:36 PM |
| Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $38,000.00 in Stock
www.americanbankingnews.com - January 11 at 12:32 PM |
| Bank Sa Swissquote Sells 72,630 Shares of Cytori Therapeutics Inc (CYTX) Stock
www.americanbankingnews.com - January 11 at 12:32 PM |
| Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today
finance.yahoo.com - January 6 at 9:35 AM |
| Cytori Therapeutics jumps as Maxim sees it as takeover candidate
seekingalpha.com - January 5 at 7:02 PM |
| Cytori Therapeutics (CYTX) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - January 5 at 6:28 PM |
| Cytori Therapeutics Inc (CYTX) Short Interest Down 35.6% in December
www.americanbankingnews.com - January 1 at 1:16 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 5:14 PM |
| Financial Analysis: Haemonetics (HAE) & Cytori Therapeutics (CYTX)
www.americanbankingnews.com - December 16 at 1:34 PM |
| Head-To-Head Analysis: Cytori Therapeutics (CYTX) and Symmetry Medical (SMA)
www.americanbankingnews.com - December 12 at 3:24 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:10 PM |
| Cytori Therapeutics (CYTX) & Inogen (INGN) Critical Comparison
www.americanbankingnews.com - December 5 at 1:38 AM |
| Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?
finance.yahoo.com - November 30 at 5:12 PM |
Cytori Therapeutics (NASDAQ:CYTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytori Therapeutics (NASDAQ:CYTX) Income Statement, Balance Sheet and Cash Flow Statement
Cytori Therapeutics (NASDAQ CYTX) Stock Chart for Friday, April, 20, 2018
Loading chart…
